Pharmacogenetics in reproductive and perinatal medicine.
The clinical application of pharmacogenetics has been well accepted by some medical specialties, but not all. The aim of this review is to discuss the current use of pharmacogenetics in reproductive and perinatal medicine and to highlight areas where pharmacogenetics may be able to help in the future to predict response to medicines in terms of efficacy and safety. This applies to drugs that are specific to pregnancy and reproduction, as well as drugs prescribed for the treatment of medical disorders in pregnancy. Our review points out the need for well-designed clinical studies on the efficacy and safety of medicines used in women of childbearing age in order to define the additional utility provided by pharmacogenetic testing.
Alfirevic
Ana
A
Department of Pharmacology & Therapeutics, Sherrington Building, Ashton Street, University of Liverpool, Liverpool, Merseyside, L69 3GE, UK. Ana.Alfirevic@liv.ac.uk
Alfirevic
Zarko
Z
Pirmohamed
Munir
M
D001623:Betamethasone / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000187:drug effects; D005492:Folic Acid / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects / Q000196:embryology; D010053:Ovary / Q000187:drug effects; D018743:Perinatal Care; D010597:Pharmacogenetics; D011225:Pre-Eclampsia / Q000188:drug therapy; D011247:Pregnancy / Q000187:drug effects; D018456:Reproductive Medicine; D015145:Tocolysis
D003907:Dexamethasone; D005492:Folic Acid; D001623:Betamethasone